Insulet Stock Forecast, Price & News

10 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Insulet in the last year. There are currently 2 hold ratings and 8 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" Insulet stock.
View analyst ratings for Insulet or view top-rated stocks.

10 Wall Street research analysts have issued twelve-month price targets for Insulet's shares. Their PODD stock forecasts range from $230.00 to $350.00. On average, they predict Insulet's share price to reach $290.36 in the next twelve months. This suggests a possible upside of 30.8% from the stock's current price.
View analysts' price targets for Insulet or view top-rated stocks among Wall Street analysts.

Insulet's stock was trading at $266.07 at the start of the year. Since then, PODD shares have decreased by 16.6% and is now trading at $221.94.
View the best growth stocks for 2022 here.

Insulet is scheduled to release its next quarterly earnings announcement on Thursday, August 4th 2022.
View our earnings forecast for Insulet.

Insulet Co. (NASDAQ:PODD) posted its quarterly earnings results on Thursday, May, 5th. The medical instruments supplier reported $0.40 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.23 by $0.17. The medical instruments supplier earned $295.40 million during the quarter, compared to the consensus estimate of $287.99 million. Insulet had a net margin of 3.91% and a trailing twelve-month return on equity of 15.81%. The company's quarterly revenue was up 17.1% on a year-over-year basis.
View Insulet's earnings history.

Insulet updated its FY 2022 earnings guidance on Monday, May, 23rd. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $1.23 billion-$1.27 billion, compared to the consensus revenue estimate of $1.24 billion.

61 employees have rated Insulet CEO Shacey Petrovic on Glassdoor.com. Shacey Petrovic has an approval rating of 55% among Insulet's employees. This puts Shacey Petrovic in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

Some companies that are related to Insulet include Abbott Laboratories (ABT), Medtronic (MDT), Stryker (SYK), Intuitive Surgical (ISRG), Becton, Dickinson and (BDX), Edwards Lifesciences (EW), Boston Scientific (BSX), Baxter International (BAX), ResMed (RMD), IDEXX Laboratories (IDXX), DexCom (DXCM), STERIS (STE), Hologic (HOLX), Teleflex (TFX) and Abiomed (ABMD).
View all of PODD's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Insulet investors own include NVIDIA (NVDA), DexCom (DXCM), Netflix (NFLX), Alibaba Group (BABA), Tesla (TSLA), Square (SQ), Walt Disney (DIS), Salesforce (CRM), Roku (ROKU) and Trade Desk (TTD).

Insulet trades on the NASDAQ under the ticker symbol "PODD."

Shares of PODD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of PODD stock can currently be purchased for approximately $221.94.

Insulet (NASDAQ:PODD) has a market capitalization of $15.39 billion and generates $1.10 billion in revenue each year. The medical instruments supplier earns $16.80 million in net income (profit) each year or $0.629990 on an earnings per share basis.

Insulet employs 2,300 workers across the globe.

Insulet was founded in 2000.

Insulet's mailing address is 100 NAGOG PARK, ACTON MA, 01720. The official website for Insulet is www.insulet.com. The medical instruments supplier can be reached via phone at (978) 600-7000, via email at [email protected], or via fax at 978-600-0120.